Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
Abstract Background Surgical resection of metastatic disease in patients with initially non-resectable colorectal cancer (CRC) has improved overall survival. Intensified chemotherapy regimens have increased the probability of converting unresectable metastasis to resectable. Here, we report the resu...
Main Authors: | Mahmoud A. Elshenawy, Ahmed Badran, Ali Aljubran, Ahmed Alzahrani, M. Shahzad Rauf, Abdelmoneim Eldali, Shouki Bazarbashi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12957-020-01930-8 |
Similar Items
-
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
by: Lin Shui, et al.
Published: (2018-08-01) -
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
by: Hironaga Satake, et al.
Published: (2020-11-01) -
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
by: Chiara Cremolini, et al.
Published: (2017-06-01) -
Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
by: Masaaki Miyo, et al.
Published: (2020-07-01) -
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature
by: Stein Alexander, et al.
Published: (2012-08-01)